VenoStent Raises $4M in Funding for Dialysis Device and Clinical Trial
VenoStent Completes $20M Series A with $4M Investment from Norwest Venture Partners
VenoStent raises $20M in Series A Financing and SBIR Grant
VenoStent (Linkedin), a leading medical device company in the United States, has secured an additional $4 million in funding, bringing their Series A financing to $20 million. With a focus on improving dialysis patient outcomes, VenoStent aims to collaborate with medical device manufacturers, hospitals, and dialysis centers to enhance CKD treatment.
Funding Amount: $20 million
Industry: Medical Equipment Manufacturing
Employee Count: 11-50
CEO: Timothy Boire (CEO Linkedin)
What VenoStent needs to buy: VenoStent is seeking partnerships with research institutions, healthcare providers, and manufacturers to support their clinical trials, produce their bioabsorbable perivascular wrap, and ensure regulatory compliance. Companies specializing in medical device manufacturing, clinical trial support, and regulatory compliance services are encouraged to explore collaboration opportunities with VenoStent.